Aptevo Therapeutics Inc.
APVO Healthcare Biotechnology
Aptevo Therapeutics Inc.’s revenue for fiscal 2022 (year ended December 2022) was $3.1 million. In the quarter to June 2026, EPS grew 96.5% and free cash flow grew 23.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow APVO
A Cash Flow Statement is a financial report that details the cash inflows and outflows of a company over a specific period. It is divided into three sections: operating activities, investing activities, and financing activities. This statement helps assess the company’s liquidity, solvency, and overall financial health. By tracking cash movements, it provides insights into the company's ability to generate cash to fund operations, pay debts, and invest in growth. Businesses and investors use it to evaluate the sustainability of a company's cash flow and its financial stability.
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Net Income |
(112.41) | 6.97 | (53.69) | (40.45) | (17.75) | (28.46) | 8.03 | (17.41) | (24.13) | (25.97) |
Depreciation & Amortization |
3.36 | 3.13 | 2.39 | 2.24 | 1.41 | 1.14 | 0.90 | 0.57 | 0.35 | 0.24 |
Non Cash Items (Other) |
58.56 | (47.18) | 3.13 | (1.98) | (10.57) | 8.29 | (32.09) | 2.20 | 2.17 | 1.19 |
Accounts Receivable Change |
2.17 | (1.83) | (3.08) | — | — | — | — | — | — | — |
Change in inventories |
13.68 | (0.57) | (0.76) | — | — | — | — | — | — | — |
Accounts Payable Change |
2.48 | 0.20 | 1.28 | (2.70) | (0.70) | (1.91) | (0.39) | 0.52 | (1.02) | (0.16) |
Income tax paid |
1.38 | — | — | — | — | — | — | — | — | — |
Change in other assets and liabilities |
(6.08) | (2.29) | (0.69) | 0.51 | (1.70) | (0.74) | 2.54 | 2.39 | (1.16) | (0.89) |
Operating Cash Flow |
(36.86) | (41.57) | (51.42) | (42.38) | (29.32) | (21.68) | (21.02) | (11.73) | (23.78) | (25.59) |
Capital expenditures |
(2.51) | (1.40) | (0.98) | (0.15) | (0.09) | (0.71) | (0.03) | — | — | — |
Net Aquisitions |
— | 59.76 | 0.07 | 4.25 | 28.12 | — | — | — | — | — |
Long-Term Investments Change (Net) |
(44.88) | (28.90) | 73.71 | — | — | — | — | — | — | — |
Investing cash flow |
(47.39) | 29.46 | 72.80 | 4.10 | 28.03 | (0.71) | (0.03) | — | — | — |
Repayment/Issuance of Debt (Net) |
18.04 | — | — | (0.14) | 2.63 | (10.55) | (12.27) | (3.47) | — | — |
Equity Repurchase (Common, Net) |
0.04 | 0.44 | 0.62 | 20.34 | 21.26 | 11.44 | 6.93 | 9.48 | 15.60 | 38.50 |
Other financial activities |
71.22 | 19.09 | (1.41) | (0.06) | (0.01) | 25.27 | 2.72 | (0.01) | 0.00 | — |
Financing cash flow |
89.30 | 19.53 | (0.79) | 20.15 | 23.87 | 26.16 | (2.62) | 6.00 | 15.60 | 38.50 |
Change in Cash |
5.04 | 7.42 | 20.59 | (18.14) | 22.59 | 3.77 | (23.67) | (5.73) | (8.19) | 12.91 |
Beginning Cash |
4.64 | 10.08 | 17.50 | 38.08 | 19.95 | 42.53 | 46.30 | 22.64 | 16.90 | 8.71 |
Ending Cash |
9.68 | 17.50 | 38.08 | 19.95 | 42.53 | 46.30 | 22.64 | 16.90 | 8.71 | 21.62 |
Stock Based Compensation |
3.81 | 4.88 | 2.14 | 1.60 | 1.26 | 1.64 | 1.80 | 2.19 | 1.07 | 0.10 |
Dividends Paid (Common) |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash/Marketcap |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Assets Liabilities Change (Total) |
13.63 | (4.50) | (3.25) | (2.19) | (2.41) | (2.65) | 2.14 | 2.91 | (2.18) | (1.05) |
Investments Change (Net) |
(44.88) | (28.90) | 73.71 | — | — | — | — | — | — | — |
Issuance/Purchase of Shares |
0.04 | 0.44 | 0.62 | 20.34 | 21.26 | 11.44 | 6.93 | 9.48 | 15.60 | 38.50 |
| Other line items | ||||||||||
Revenue per Employee |
0.08 | 0.12 | 0.20 | 0.41 | 0.07 | 0.23 | 0.07 | 0.00 | 0.00 | 0.00 |